Insider Transactions in Q4 2025 at Royalty Pharma PLC (RPRX)
Insider Transaction List (Q4 2025)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 31
2025
|
Bonnie L Bassler Director |
BUY
Grant, award, or other acquisition
|
Direct |
967
+1.31%
|
$36,746
$38.74 P/Share
|
|
Dec 26
2025
|
Marshall Urist EVP, Research & Investments |
SELL
Open market or private sale
|
Indirect |
20,000
-16.67%
|
$780,000
$39.32 P/Share
|
|
Dec 19
2025
|
Marshall Urist EVP, Research & Investments |
SELL
Open market or private sale
|
Indirect |
20,000
-14.29%
|
$760,000
$38.38 P/Share
|
|
Dec 18
2025
|
George W. Lloyd EVP, Investments & CLO |
SELL
Open market or private sale
|
Indirect |
30,654
-100.0%
|
$1,164,852
$38.5 P/Share
|
|
Dec 17
2025
|
George W. Lloyd EVP, Investments & CLO |
SELL
Open market or private sale
|
Indirect |
79,346
-72.13%
|
$3,015,148
$38.57 P/Share
|
|
Dec 16
2025
|
Marshall Urist EVP, Research & Investments |
SELL
Open market or private sale
|
Indirect |
20,000
-12.5%
|
$760,000
$38.32 P/Share
|
|
Dec 15
2025
|
Terrance P. Coyne EVP & CFO |
SELL
Open market or private sale
|
Indirect |
69,582
-9.52%
|
$2,644,116
$38.36 P/Share
|
|
Dec 05
2025
|
Marshall Urist EVP, Research & Investments |
SELL
Open market or private sale
|
Direct |
18,242
-71.15%
|
$711,438
$39.15 P/Share
|
|
Dec 05
2025
|
Marshall Urist EVP, Research & Investments |
SELL
Open market or private sale
|
Indirect |
23,334
-12.73%
|
$910,026
$39.15 P/Share
|
|
Dec 03
2025
|
George W. Lloyd EVP, Investments & CLO |
SELL
Open market or private sale
|
Indirect |
110,000
-50.0%
|
$4,290,000
$39.77 P/Share
|
|
Dec 01
2025
|
Marshall Urist EVP, Research & Investments |
SELL
Open market or private sale
|
Direct |
18,242
-41.57%
|
$711,438
$39.9 P/Share
|
|
Dec 01
2025
|
Marshall Urist EVP, Research & Investments |
SELL
Open market or private sale
|
Indirect |
23,333
-11.29%
|
$909,987
$39.93 P/Share
|
|
Dec 01
2025
|
Terrance P. Coyne EVP & CFO |
SELL
Open market or private sale
|
Indirect |
69,582
-8.68%
|
$2,713,698
$39.87 P/Share
|
|
Nov 24
2025
|
Terrance P. Coyne EVP & CFO |
SELL
Open market or private sale
|
Indirect |
69,582
-4.03%
|
$2,644,116
$38.31 P/Share
|
|
Nov 19
2025
|
George W. Lloyd EVP, Investments & CLO |
SELL
Open market or private sale
|
Direct |
3,000
-96.17%
|
$114,000
$38.66 P/Share
|
|
Nov 19
2025
|
George W. Lloyd EVP, Investments & CLO |
SELL
Open market or private sale
|
Indirect |
132,426
-84.54%
|
$5,032,188
$38.64 P/Share
|
|
Nov 17
2025
|
Terrance P. Coyne EVP & CFO |
SELL
Open market or private sale
|
Indirect |
69,594
-7.37%
|
$2,714,166
$39.3 P/Share
|
|
Nov 07
2025
|
Marshall Urist EVP, Research & Investments |
BUY
Conversion of derivative security
|
Indirect |
160,000
+43.64%
|
-
|
|
Nov 05
2025
|
Marshall Urist EVP, Research & Investments |
BUY
Grant, award, or other acquisition
|
Direct |
4,626
+9.54%
|
-
|
|
Nov 05
2025
|
Christopher Hite EVP & Vice Chairman |
BUY
Grant, award, or other acquisition
|
Indirect |
6,168
+0.93%
|
-
|
|
Nov 05
2025
|
George W. Lloyd EVP, Investments & CLO |
BUY
Grant, award, or other acquisition
|
Indirect |
6,168
+9.54%
|
-
|
|
Nov 05
2025
|
Terrance P. Coyne EVP & CFO |
BUY
Grant, award, or other acquisition
|
Indirect |
6,168
+9.54%
|
-
|
|
Nov 05
2025
|
Legorreta Pablo G. CEO, Chairman of the Board |
BUY
Grant, award, or other acquisition
|
Direct |
36,559
+3.74%
|
-
|